Last reviewed · How we verify

NCT03436342

Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma

Status unknown EARLY_PHASE1 Last updated 27 December 2019
What this trial tests

EARLY_PHASE1 trial testing 68Ga-Pentixafor in Multiple Myeloma in 100 participants. Status unknown.

Timeline
1 June 2019
Primary endpoint
1 March 2020
1 December 2020

Quick facts

Lead sponsorPeking Union Medical College Hospital
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment100
Start date1 June 2019
Primary completion1 March 2020
Estimated completion1 December 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Multiple Myeloma or Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chemokine receptor CXCR4 was expressed in MM and lymphoma cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of MM and lymphoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and prognostic evaluation of MM and lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.
    Santagata S, Ieranò C, Trotta AM, Capiluongo A, et al · · 2021 · cited 74× · PMID 33937018 · DOI 10.3389/fonc.2021.591386
  2. Chemokine receptor-4 targeted PET/CT with <sup>68</sup>Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to <sup>18</sup>F-FDG PET/CT.
    Pan Q, Cao X, Luo Y, Li J, et al · · 2020 · cited 72× · PMID 31776631 · DOI 10.1007/s00259-019-04605-z
  3. Novel Agents and Future Perspectives on Theranostics.
    Solnes LB, Shokeen M, Pandit-Taskar N. · · 2021 · cited 12× · PMID 33246639 · DOI 10.1016/j.semradonc.2020.07.010
  4. Positron Emission Tomography Molecular Imaging for Phenotyping and Management of Lymphoma.
    Zhang X, Jiang H, Wu S, Wang J, et al · · 2022 · cited 9× · PMID 36939797 · DOI 10.1007/s43657-021-00042-x
  5. Current and Future PET Imaging for Multiple Myeloma.
    Ishibashi M, Takahashi M, Yamaya T, Imai Y. · · 2023 · cited 4× · PMID 37629558 · DOI 10.3390/life13081701
  6. <sup>68</sup>Ga-Pentixafor PET/CT May Fail to Detect Recurrent Multiple Myeloma with Extramedullary Disease.
    Pan Q, Luo Y, Cao X, Li J, et al · · 2023 · cited 1× · PMID 36900014 · DOI 10.3390/diagnostics13050871
  7. Reduced splenic uptake of [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-Pentixafor following first-line chemotherapy is associated with poor prognosis in patients with newly diagnosed multiple myeloma.
    Pan Q, Chen Z, Liu S, Zhang H, et al · · 2025 · PMID 40540129 · DOI 10.1186/s13550-025-01262-2
  8. Investigating CXCR4 expression of tumor cells and the vascular compartment: A multimodal approach.
    Braga M, Leow CH, Gil JH, Teh JH, et al · · 2021 · PMID 34793563 · DOI 10.1371/journal.pone.0260186

Verify or expand the search:

Other trials of 68Ga-Pentixafor

Trials testing the same drug.

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03436342.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing